This site is intended for health professionals only
Newsletter
Hospital Healthcare Europe
Login
Twitter
Linkedin
Facebook
Select Language
English
French
German
Italian
Spanish
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Clinical Excellence
Cardiology
Respiratory
Events
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Clinical Excellence
Cardiology
Respiratory
Events
Home
>
Endocrine disorders
Endocrine disorders
CFS drug shows promise at Phase 3
Phase III first for Cushing’s disease drug
EMA recommends pasireotide for Cushing’s disease
Oxytocin positively affects Prader-Willi syndrome
Levothyroxine Sodium for Injection FDA approval announced
Phase II study shows objective response rate in thyroid cancer
Follicle-stimulating hormone trial starts
Thyroid medication warning issued
Thyroid cancer drug approved
Drug combination beats obesity
Male hormone linked to heart deaths
SOM230 is first medical therapy to show efficacy in a Phase III trial in Cushing’s disease
« Previous
1
2
3
4
5
…
7
Next »
Most read
1
Transcranial magnetic stimulation brain connectivity changes in major depression visible on MRI scan
by Rod Tucker
2
Oral vitamin A could become an alternative to isotretinoin for acne
by Rod Tucker
3
Amino acids supplement reduces muscle wasting and improves gut function in critically ill
by Rod Tucker
4
Less than two-thirds of patients alive 10 years after out-of-hospital cardiac arrest
by Rod Tucker
5
Launch of the new Hospital Pharmacy Europe Mobile App
by aporter2
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
x
Search for: